Similar articles

• Should bivalirudin replace heparin during percutaneous coronary interventions?

  Antman EM. Antman EM. JAMA. 2003 Feb 19;289(7):903-5. doi: 10.1001/jama.289.7.903. JAMA. 2003. PMID: 12588276 No abstract available.
• Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.

  Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ; REPLACE-2 Investigators. Lincoff AM, et al. JAMA. 2003 Feb 19;289(7):853-63. doi: 10.1001/jama.289.7.853. JAMA. 2003. PMID: 12588269 Clinical Trial.
• Provisional use of glycoprotein IIb/IIIa inhibitors in the era of dual antiplatelet therapy--do "bailouts" pay off?

  Jeremias A, Gruberg L. Jeremias A, et al. J Invasive Cardiol. 2009 Jun;21(6):264-5. J Invasive Cardiol. 2009. PMID: 19494401 No abstract available.
• Direct thrombin inhibitors (part 2 of 2).

  Arora UK, Dhir M. Arora UK, et al. J Invasive Cardiol. 2005 Feb;17(2):85-91. J Invasive Cardiol. 2005. PMID: 15687531 Review. No abstract available.
• Combination platelet glycoprotein IIb/IIIa receptor and lepirudin administration during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia.

  Pinto DS, Sperling RT, Tu TM, Cohen DJ, Carrozza JP Jr. Pinto DS, et al. Catheter Cardiovasc Interv. 2003 Jan;58(1):65-8. doi: 10.1002/ccd.10393. Catheter Cardiovasc Interv. 2003. PMID: 12508198 Review.